Adlai Nortye to Present Promising AN0025 and dCRT Data at ASCO 2024

Adlai Nortye Ltd., a clinical-stage biotechnology company with a focus on innovative cancer treatments, has revealed promising early data concerning their drug AN0025. The data will be discussed at the American Society of Cancer Oncology (ASCO) Annual Meeting from May 31 to June 4, 2024, in Chicago. The company, recognized on NASDAQ as ANL, is committed to developing significant cancer therapies to meet global patient needs.

AN0025 is a targeted EP4 inhibitor known for its antitumor properties. These properties are exhibited by influencing macrophages and immunosuppressive myeloid cells within the tumor environment. In prior clinical research, when AN0025 was combined with chemoradiotherapy (CRT) as a neoadjuvant therapy, it demonstrated enhanced antitumor efficacy in patients with advanced rectal cancer. This previous study, identified as NCT03152370, set a promising precedent for its current evaluation.

The current study, AN0025S0104, is a Phase Ib clinical trial designed as a single-arm, open-label, multicenter study. The trial includes a dose escalation phase followed by an expansion phase, aiming to assess the safety, tolerability, and practicality of combining AN0025 with definitive CRT in cases of unresectable locally advanced or recurrent esophageal cancer (EC) and esophagogastric junction cancer.

Lars Birgerson, President and Chief Medical Officer of Adlai Nortye, emphasized the company's commitment to innovative cancer therapies and global outreach. He expressed eagerness to share updates on their pipeline programs with the oncology community at the ASCO meeting.

Adlai Nortye's abstract for the ASCO 2024 meeting is detailed as follows:
- Abstract Title: AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC): a single-arm, open-label, multicenter, Phase Ib study (AN0025S0104)
- First Author: Nan Bi, Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
- Abstract Number: e16076

Adlai Nortye is an international biotechnology company that focuses on discovering and developing cutting-edge cancer therapies. The company has research and development centers in New Jersey, USA, and Hangzhou, China. They have built a strong pipeline with six drug candidates, demonstrating a strategic focus on oncology.

The company benefits from a global management team and a scientific advisory board composed of industry and academic leaders. This expertise supports their R&D, business development, and operational strategies. Adlai Nortye actively pursues partnerships with prominent pharmaceutical companies, including Eisai and Novartis, to maximize the potential of their development programs.

Their ultimate mission is to transform fatal cancer into a manageable and potentially curable condition through a combination therapy approach. Adlai Nortye aspires to become a leader in the next generation of oncology treatments.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!